Heart failure is the leading cause of mortality, and about 6.2 million adults in the United
States have heart failure. Heart failure with preserved ejection fraction (HFpEF) has
typical heart failure symptoms with mostly diastolic LV dysfunction but preserved
ejection fraction. HFpEF is characterized by pronounced coronary microvascular
dysfunction (CMD), the causal contribution of which is unclear. CMD is associated with
coronary artery diseases (CAD), diabetic cardiomyopathy (DCM), ischemia with the non-
obstructive coronary artery (INOCA), and HFpEF. Patients with CMD exhibit impaired
acetylcholine-induced endothelial-dependent relaxation. Impaired endothelium-
dependent vasodilation (EDD) decreases coronary blood flow and myocardium perfusion
and might lead to myocardial ischemia even without an obstructive coronary artery. We
hypothesize that the myocardial deficiency perfusion caused by CMD will lead to
myocardial ischemia, diastolic cardiac dysfunction, and fibrosis in HFpEF. So CMD plays
a critical role in HFpEF.
Moreover, our ex vivo study shows a deficiency of miR-21 that restores the NO-
dependent coronary vasodilation. This application will address the underlying
mechanism of how miR-21 regulates the coronary microvascular function, cardiac
function and remodeling in HFpEF in a mouse model of HFpEF induced by a long-term
high fat and high sugar diet. Such a preclinical modelof HFpEF has been validated in our
preliminary data. We hypothesize that restoring “normal” coronary microvascular
function (restoring endothelial-dependent dilation) by modulating miR-21can ameliorate
HFpEF. We will test our hypothesis by an interdisciplinary approach encompassing a
range of approaches and disciplines from molecular and cell analyses, vascular biology
to physiology and pathophysiology, engendering the study of a novel mechanism of
coronary microvascular dysfunction, such as tissue-specific knockouts and lineage
tracing with 3D fluorescent imaging, measurement of vasodilation and myocardial blood
flow in vivo by contrast echocardiography and cardiac function by echocardiography
along with RNA-seq, sc RNA-seq, etc. Completing this project may lead to a new
strategy to treat microvascular dysfunction and HFpEF and improve the cardiovascular
prognosis of HFpEF.